Fig. 2From: Imaging using radiolabelled targeted proteins: radioimmunodetection and beyondTargeting of HER2-expressing tumours in mice using positron-emitting imaging agents. a. Uptake of the antibody [89Zr]Zr-DFO*-trastuzumab in tumour, blood, kidneys and major metastatic sites. b. Uptake of small targeting probes in tumour, blood, kidneys and major metastatic sites. Data are from (Vugts et al. 2017). c Tumor-to-tissue ratios for an antibody [89Zr]Zr-DFO*-trastuzumab 144 h after injection (Vugts et al. 2017), [68Ga]Ga-ABY-025 affibody molecule 3 h after injection (Kramer-Marek et al. 2011), ADAPT [68Ga]Ga-ADAPT6 3 h after injection (Lindbo et al. 2018a, 2018b) and [68Ga]Ga-sdAb 2Rs15d 1.5 h after injection (Massa et al. 2016).Back to article page